Doseology Sciences (MOOD) AI Stock Analysis

• Market Cap: C$4.41M
• Dividend Yield: N/A
• Average Volume (3M): 1.79K
• Price to Earnings (P/E): ―
• Beta (1Y): -3.39
• Revenue Growth: -50.89%
• EPS Growth: -32.33%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.04
• Shares Outstanding: 8,011,621
• 10 Day Avg. Volume: 3,383
• 30 Day Avg. Volume: 1,793
• PEG Ratio: -0.49
• Price to Book (P/B): 3.46
• Price to Sales (P/S): 113.73
• P/FCF Ratio: -14.14
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: C$0.54 ▲(1.13% Upside)
• Action: Reiterated Date: 03/18/26
• Date: Action: Reiterated 03/18/26

The score is held down primarily by weak financial performance (low/declining revenue, sizable losses, and negative cash flow that may require external financing). Technicals also lean bearish with price below key moving averages and a slightly negative MACD. Valuation provides limited support because the negative P/E reflects unprofitability and there is no dividend yield.

Positive Factors

Strong balance sheet / low leverage

Zero reported debt and equity that exceeds assets materially reduce bankruptcy and refinancing risk, giving management flexibility to invest in product development or distribution. This structural cushion supports longevity while the business pursues scaling and new revenue streams.

Improving cash burn trend

A material improvement in cash burn versus 2022–2023 indicates improving operational discipline and lower near-term financing needs. If sustained, this trend increases the chance the company can reach self-funding or reduce dilution risk while continuing product commercialization efforts.

Consumer cannabinoid product strategy

A consumer-facing, dosage-controlled cannabinoid product strategy aligns with secular wellness trends and scalable brand-based revenues. Durable demand for regulated wellness formulations and repeatable consumer products can enable predictable unit economics once distribution and product-market fit are established.

Negative Factors

Very small, volatile revenue and losses

Persistently tiny and volatile revenue, including a year-over-year decline, means the business lacks scale to absorb fixed costs. Large ongoing operating losses indicate the current model does not generate sustainable margins, heightening execution risk and reliance on successful commercial expansion to change the trajectory.

Consistently negative operating and free cash flow

Ongoing negative operating and free cash flow force dependence on external capital to fund operations and growth. That structural financing need can dilute shareholders, limit strategic optionality, and constrain spending on marketing or R&D needed to achieve scale and improve unit economics.

Very limited operational capacity

Reporting zero employees suggests the company is extremely lean or highly outsourced, raising concerns about execution, internal controls, and rapid scaling ability. Limited in-house capacity can slow product development, quality control, and commercial rollouts over the medium term.

Doseology Sciences Business Overview & Revenue Model

Company Description

Doseology Sciences Inc. engages in the cultivation and extraction of nutraceutical and pharmaceutical products in Canada. It focuses on research, development, and sale of medicinal mushroom products, including tinctures and powders. The company sells its products online through doseology.com. Doseology Sciences Inc. was incorporated in 2019 and is based in Kelowna, Canada.

How the Company Makes Money

null

Doseology Sciences Financial Statement Overview

Summary

Financials are weak: very small and volatile revenue with large ongoing losses and consistently negative operating/free cash flow. The main offset is a relatively strong balance sheet with effectively no debt, but persistent losses and cash burn create continued funding risk.

Income Statement

Revenue remains very small and volatile (down ~27% in 2025 vs. 2024), and profitability is weak with large ongoing losses (2025 net margin roughly -10.5%). While gross profit is positive in recent years, operating losses remain sizable relative to revenue, indicating the business has not yet scaled to cover operating costs.

Balance Sheet

The balance sheet is a relative strength: debt is effectively zero in the latest two years, and equity exceeds total assets by a wide margin (suggesting limited leverage risk). However, persistent losses are eroding returns for shareholders (negative return on equity across all periods), which can pressure the equity base over time if losses continue.

Cash Flow

Cash generation is weak with consistently negative operating cash flow and negative free cash flow each year (2025 operating cash flow about -$342K). Cash burn improved materially versus prior years (notably compared with 2022–2023), but cash flow still does not support self-funding operations and leaves the company dependent on external capital if spending persists.

Breakdown	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Jun 2021
Income Statement
Total Revenue	42.56K	98.52K	43.09K	16.05K	0.00
Gross Profit	18.89K	72.09K	41.29K	-148.38K	-92.83K
EBITDA	-471.61K	-319.48K	-1.78M	-1.72M	-1.47M
Net Income	-447.79K	-339.85K	-1.78M	-1.94M	-1.63M
Balance Sheet
Total Assets	1.49M	1.10M	1.40M	3.87M	5.99M
Cash, Cash Equivalents and Short-Term Investments	1.43M	1.06M	1.30M	1.87M	3.73M
Total Debt	0.00	0.00	50.27K	746.10K	687.54K
Total Liabilities	94.11K	82.49K	99.19K	871.51K	3.41M
Stockholders Equity	1.40M	1.02M	1.30M	3.00M	2.58M
Cash Flow
Free Cash Flow	-342.24K	-235.12K	-481.05K	-1.72M	-2.54M
Operating Cash Flow	-342.24K	-235.12K	-481.05K	-1.71M	-2.37M
Investing Cash Flow	0.00	0.00	0.00	-7.88K	-26.05K
Financing Cash Flow	711.68K	-6.14K	-91.88K	-140.08K	5.79M

Doseology Sciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.53
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MOOD, the sentiment is Negative. The current price of 0.53 is below the 20-day moving average (MA) of 0.63, below the 50-day MA of 0.70, and below the 200-day MA of 0.69, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 45.05 is Neutral, neither overbought nor oversold. The STOCH value of 57.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MOOD.

Doseology Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ENBI	47 Neutral	C$1.39M	-6.62	-107.76%	―	―	34.22%
MOOD	45 Neutral	C$4.41M	-4.13	-41.36%	―	-50.89%	-32.33%
DOSE	42 Neutral	C$13.19M	-4.62	75.85%	―	95.76%	22.56%

Doseology Sciences Corporate Events

Doseology Uplists to OTCQB to Advance Growth in Oral Stimulant Pouch Market

Doseology Sciences Inc. has uplisted its common shares to the OTCQB Venture Market in the United States under the symbol DOSEF, a move aimed at expanding access for U.S. investors and aligning the company with higher standards of financial reporting and governance. The listing is supported by recent board strengthening, including the appointment of Larry Latowsky as Executive Chairman, underscoring the company’s focus on transparency and compliance as it executes its long-term growth strategy.

The company is positioning itself within the fast-growing oral stimulant pouch category, where global consumer trends are shifting toward smoke-free, portable, controlled-dose delivery formats that parallel innovation in the multi-billion-dollar energy drink market. Doseology is pursuing a platform strategy that combines product development, brand building, and digital direct-to-consumer distribution, leveraging its acquisition of the Feed That Brain brand and issuing pre-funded warrants to the seller as part of a structured, phased acquisition consideration.

By focusing on proprietary stimulant technologies, including next-generation caffeine analogs and nicotine alternatives tailored for oral pouches, Doseology aims to differentiate itself from traditional nicotine players and capture emerging demand for functional stimulant products. This strategic approach could enhance the company’s industry positioning as a specialized innovator in modern oral stimulants, with implications for investors seeking exposure to early-stage growth in this evolving consumer category.

The most recent analyst rating on (TSE:MOOD) stock is a Hold with a C$0.70 price target. To see the full list of analyst forecasts on Doseology Sciences stock, see the TSE:MOOD Stock Forecast page.

Doseology debuts nicotine-free energy pouches in U.S. direct-to-consumer pilot

Doseology Sciences has launched its Feed That Brain Energy Pouches in the U.S. through its first direct-to-consumer pilot, offering nicotine-free, caffeine-based oral stimulant pouches via its own website and Amazon. The product aims to deliver controlled, sugar-free energy in a discreet format, aligning with growing demand for portable and smokeless delivery systems.

The U.S. pilot is a strategic milestone intended to validate oral pouches as a scalable stimulant platform and to gather data on adoption, usage, and repeat purchases, especially among consumers seeking alternatives to energy drinks. Doseology also granted restricted and performance share units to a director, tying compensation to long-term performance as it positions itself within the fast-growing pouch-based functional products market.

The most recent analyst rating on (TSE:MOOD) stock is a Hold with a C$0.63 price target. To see the full list of analyst forecasts on Doseology Sciences stock, see the TSE:MOOD Stock Forecast page.

Doseology Taps Veteran Pharmacy Executive Larry Latowsky as Executive Chairman to Steer Commercial Expansion

Doseology Sciences has appointed veteran retail and healthcare executive Larry Latowsky as a director and Executive Chairman of its board, signaling a governance and leadership upgrade as it prepares to scale its precision-controlled oral stimulant delivery platform. Latowsky’s track record leading major pharmacy chains, overseeing regulated manufacturing and distribution, and guiding health-focused e-commerce platforms is expected to bolster Doseology’s strategic execution, credibility with investors, and ability to build a durable, disciplined growth platform in a nascent but sizable North American market.

In connection with his appointment, Doseology granted Latowsky a package of restricted and performance share units, underscoring long-term alignment with the company’s performance and milestone achievement. Management frames the hire as a critical step in moving from early innovation toward broader commercialization, leveraging Latowsky’s experience with large-scale transactions, corporate governance, and network-driven partnerships to differentiate the company from less disciplined competitors in the evolving oral stimulant and nicotine-adjacent sectors.

The most recent analyst rating on (TSE:MOOD) stock is a Hold with a C$0.69 price target. To see the full list of analyst forecasts on Doseology Sciences stock, see the TSE:MOOD Stock Forecast page.

Doseology Launches Pilot for Caffeine Energy Pouches Under Feed That Brain Brand

Doseology Sciences has begun a pilot production run of non-nicotine, caffeine-based energy pouches under its Feed That Brain brand, positioning the platform at the center of its broader oral stimulant strategy. The initiative is designed as a controlled, data-driven test of pouch-based caffeine delivery, emphasizing measured, predictable energy and user control rather than intensity, and will use limited direct-to-consumer distribution to gather product, consumer, and operational insights that could shape future formulations, delivery formats, and commercialization in the rapidly expanding, yet increasingly scrutinized, global energy-products market.

The most recent analyst rating on (TSE:MOOD) stock is a Hold with a C$0.77 price target. To see the full list of analyst forecasts on Doseology Sciences stock, see the TSE:MOOD Stock Forecast page.

Doseology Boosts Transparency With New Annual Information Form Filing

Doseology Sciences Inc. has filed its Annual Information Form for the fiscal year ended June 30, 2025 on SEDAR+, consolidating its business, strategy, risk factors, governance practices, and capital structure into a single, structured disclosure document. The move is positioned as a governance and transparency measure aimed at improving investors’ access to information and preserving future capital markets flexibility, including potential short-form prospectus eligibility, while the company stresses that no financing or public offering is being announced at this time and that the filing reflects its evolved operating profile following platform development and its first acquisition.

The most recent analyst rating on (TSE:MOOD) stock is a Hold with a C$0.78 price target. To see the full list of analyst forecasts on Doseology Sciences stock, see the TSE:MOOD Stock Forecast page.

Doseology Taps McKinney Advisors to Fast-Track Regulatory Path for Oral Pouch Line

Doseology Sciences has entered a strategic partnership with McKinney Regulatory Science Advisors to accelerate the regulatory and commercial development of its innovative oral pouch products. The engagement is designed to fast-track the company’s navigation of FDA pathways, particularly for nicotine and nicotine-analogue formulations, by integrating regulatory strategy into formulation, testing, manufacturing validation, and post-market compliance. By leveraging McKinney’s expertise in PMTA preparation, labelling, claims, and surveillance, Doseology aims to strengthen its intellectual property, ensure dose consistency and consumer safety, and position itself as a science-led frontrunner in the emerging market for regulated oral stimulant pouches.

The most recent analyst rating on (TSE:MOOD) stock is a Hold with a C$0.70 price target. To see the full list of analyst forecasts on Doseology Sciences stock, see the TSE:MOOD Stock Forecast page.